Publications 2025

Dybedal I, Iversen N, Jacobsen AF, Bjørge L, Chaireti R, Henriksson CE, Schultz NH, Hvas AM, Sandset PM, Weedon-Fekjær H, Bremme K, Abildgaard U (2025)
Hereditary antithrombin deficiency and venous thrombosis in pregnancy-results of a retrospective multicenter study
J Thromb Haemost (in press)
DOI 10.1016/j.jtha.2025.03.001, PubMed 40086756

Publications 2024

Holm S, Michelsen AE, Schultz NH, Ueland T, Reikvam H, Holme PA, Aukrust P, Halvorsen B (2024)
Human papilloma virus vaccine induced thrombocytopenia accompanied by a wide spectrum of reversible inflammatory responses - a case report
Scand J Clin Lab Invest, 84 (6), 425-427
DOI 10.1080/00365513.2024.2400663, PubMed 39264796

Røed-Undlien H, Schultz NH, Amundsen EK, Wollmann BM, Molden E, Akerkar RR, Bjørnstad JL (2024)
Does in vitro hemolysis affect measurements of plasma apixaban concentration by UPLC-MS and anti-Xa assay?
Int J Lab Hematol, 46 (5), 946-952
DOI 10.1111/ijlh.14311, PubMed 38808488

Røed-Undlien H, Schultz NH, Husebråten IM, Wollmann BM, Akerkar RR, Molden E, Amundsen EK, Bjørnstad JL (2024)
Apixaban removal during emergency surgery for type A acute aortic dissection: a prospective cohort study
Int J Surg, 110 (12), 7782-7790
DOI 10.1097/JS9.0000000000002137, PubMed 39806740

Røed-Undlien H, Schultz NH, Lunnan A, Husebråten IM, Wollmann BM, Molden E, Bjørnstad JL (2024)
Corrigendum to < IN-VITRO APIXABAN REMOVAL BY CYTOSORB® WHOLE BLOOD ADSORBER. AN EXPERIMENTAL STUDY.> <[Journal of Cardiothoracic and Vascular Anesthesia 36/6 (2024) 1636 - 1644]>
J Cardiothorac Vasc Anesth, 38 (7), 1606-1607
DOI 10.1053/j.jvca.2024.03.039, PubMed 38580477

Publications 2023

Fagerhol MK, Schultz NH, Mirlashari MR, Wiedmann MKH, Nissen-Meyer LSH, Søraas AVL, Hetland G (2023)
DNase analysed by a novel competitive assay in patients with complications after ChAdOx1 nCoV-19 vaccination and in normal unvaccinated blood donors
Scand J Immunol, 98 (1), e13274
DOI 10.1111/sji.13274, PubMed 37676118

Schultz NH, Bechensteen AG, Tjønnfjord EB, Akkök ÇA, Berg MH (2023)
New interest group for red blood cell disorders
Tidsskr Nor Laegeforen, 143 (3)
DOI 10.4045/tidsskr.22.0731, PubMed 36811425

Publications 2022

Hetland G, Fagerhol MK, Wiedmann MKH, Søraas AVL, Mirlashari MR, Nissen-Meyer LSH, Istre MS, Holme PA, Schultz NH (2022)
Elevated NETs and Calprotectin Levels after ChAdOx1 nCoV-19 Vaccination Correlate with the Severity of Side Effects
Vaccines (Basel), 10 (8)
DOI 10.3390/vaccines10081267, PubMed 36016155

Røed-Undlien H, Schultz NH, Lunnan A, Husebråten IM, Wollmann BM, Molden E, Bjørnstad JL (2022)
In Vitro Apixaban Removal By CytoSorb Whole Blood Adsorber: An Experimental Study
J Cardiothorac Vasc Anesth, 36 (6), 1636-1644
DOI 10.1053/j.jvca.2022.01.038, PubMed 35272914

Schultz NH, Søraas AVL, Sørvoll IH, Akkök ÇA, Vetlesen A, Bhamra JS, Ahlen MT, Holme PA, Aamodt AH, Skagen K, Skattør TH, Skjelland M, Wiedmann MK (2022)
Vaccine associated benign headache and cutaneous hemorrhage after ChAdOx1 nCoV-19 vaccine: A cohort study
J Stroke Cerebrovasc Dis, 32 (1), 106860
DOI 10.1016/j.jstrokecerebrovasdis.2022.106860, PubMed 36403363

Tarasco E, von Krogh AS, Hrdlickova R, Braschler TR, Iwaniec T, Knöbl PN, Hamada E, Pikovsky O, Farese S, Gutwein O, Kessler P, Schultz NH, von Auer C, Windyga J, Friedman K, Hrachovinova I, George JN, Matsumoto M, Schneppenheim R, Lämmle B, Kremer Hovinga JA (2022)
Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease
Res Pract Thromb Haemost, 6 (7), e12814
DOI 10.1002/rth2.12814, PubMed 36284639

Publications 2021

Holm S, Kared H, Michelsen AE, Kong XY, Dahl TB, Schultz NH, Nyman TA, Fladeby C, Seljeflot I, Ueland T, Stensland M, Mjaaland S, Goll GL, Nissen-Meyer LS, Aukrust P, Skagen K, Gregersen I, Skjelland M, Holme PA, Munthe LA, Halvorsen B (2021)
Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
Eur Heart J, 42 (39), 4064-4072
DOI 10.1093/eurheartj/ehab506, PubMed 34405870

Schultz NH, Fareed J, Holme PA (2021)
Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors-An In Vitro Study
Clin Appl Thromb Hemost, 27, 10760296211021156
DOI 10.1177/10760296211021156, PubMed 34060371

Schultz NH, Glosli H, Bjørnsen S, Holme PA (2021)
The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study
Res Pract Thromb Haemost, 5 (5), e12561
DOI 10.1002/rth2.12561, PubMed 34263107

Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skattør TH, Tjønnfjord GE, Holme PA (2021)
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
N Engl J Med, 384 (22), 2124-2130
DOI 10.1056/NEJMoa2104882, PubMed 33835768

Wiedmann M, Skattør T, Stray-Pedersen A, Romundstad L, Antal EA, Marthinsen PB, Sørvoll IH, Leiknes Ernstsen S, Lund CG, Holme PA, Johansen TO, Brunborg C, Aamodt AH, Schultz NH, Skagen K, Skjelland M (2021)
Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series
Front Neurol, 12, 721146
DOI 10.3389/fneur.2021.721146, PubMed 34393988

Publications 2019

Schultz NH, Holme PA, Henriksson CE, Mowinckel MC, Sandset PM, Bratseth V, Jacobsen EM (2019)
The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis
Thromb Res, 177, 154-156
DOI 10.1016/j.thromres.2019.03.010, PubMed 30903875

Publications 2018

Schultz NH, Holme PA, Bjørnsen S, Henriksson CE, Sandset PM, Jacobsen EM (2018)
The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis
Platelets, 31 (1), 43-47
DOI 10.1080/09537104.2018.1557618, PubMed 30569801

Schultz NH, Lundblad R, Holme PA (2018)
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
J Med Case Rep, 12 (1), 138
DOI 10.1186/s13256-018-1660-9, PubMed 29764497

Publications 2017

Schultz NH, Tran HTT, Bjørnsen S, Henriksson CE, Sandset PM, Holme PA (2017)
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Thromb J, 15, 6
DOI 10.1186/s12959-017-0129-1, PubMed 28239301

Schultz NH, Tran HTT, Bjørnsen S, Henriksson CE, Sandset PM, Holme PA (2017)
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro
Res Pract Thromb Haemost, 1 (1), 49-56
DOI 10.1002/rth2.12015, PubMed 30046673